Biotechnology major Biocon on Wednesday reported a 71 per cent increase in consolidated net profit at Rs 144 crore for the June quarter on the back of robust growth across business verticals. The company had posted a net profit of Rs 84 crore in the April-June quarter of the previous fiscal. Total revenue rose to Rs 2,217 crore in the first quarter as compared with Rs 1,808 crore in the year-ago period, Biocon said in a regulatory filing. Biocon Executive Chairperson Kiran Mazumdar-Shaw said revenues grew as a result of robust growth in both biosimilar and generics verticals. "Our financial performance this quarter includes the impact of annual increments in personnel costs as well as increased input and freight costs, pursuant to pandemic and geopolitical disruptions of global supply chains," she added. All the company businesses are poised for the next phase of sustainable growth which has been challenged during the two years of the Covid pandemic, Mazumdar-Shaw said.
Biotechnology major Biocon on Thursday said the US health regulator has issued three observations after inspecting its Telangana-based manufacturing plant. The US Food and Drug Administration (USFDA) concluded a pre-approval inspection for Site 3 located at Hyderabad on July 20, Biocon Ltd said in a regulatory filing. "Three observations were cited at the end of the inspection, which we will be addressing within the stipulated time," it added. The company stands committed to quality, safety and efficacy of its products, the Bengaluru-based company said.
Approval comes from Irish health regulator, which had flagged some deficiencies in the manufacturing process iin May
Guljit Sethi of Bioinnovat was named in CBI FIR on a bribery case involving CDSCO official and Biocon Biologics executive
Stocks to Watch Today: Among airline shares, SpiceJet has reported seven aircraft related incidents in the last two months; while IndiGo said has hired over 1,500 cabin crew staff to counter likely at
The high court, however, directed the jail superintendent to hand over the custody of associate vice president of Biocon Biologics L Praveen Kumar
15% turnover investment in research could make companies eligible for the scheme
The company has entered into an agreement for the purpose of "acquisition of solar power by acquiring equity stake up to 26 per cent in AREREPL", it said.
Stocks to watch today: Akash M Ambani will take over as non-executive director and chairman of the board of directors of Reliance Jio; Tata Motors will hike prices of CVs by 1.5 to 2.5 per cent.
CBI on Tuesday moved the Delhi High Court seeking the custody of officials accused of allegedly demanding bribes to waive the Phase-3 trial of "Insulin Aspart Injection"
The Delhi High Court has issued notices to the parties concerned and will hear the case on July 2
Stocks to watch today: Adani Enterprises subsidiary raised over Rs 6,000 crore to set up greenfield copper refinery; State-run IOB will boost advances across retail, corporate and MSME loans this year
All five apprehended will be presented in court on Tuesday afternoon, agency to seek police custody
The company said its product approvals are backed by science and clinical data
The CBI registered a case of criminal conspiracy and corruption against Reddy, posted at CDSCO headquarters, and Dinesh Dua, Director at Synergy Network India Private Limited, among others.
In the past one year, the stock has slipped 22 per cent, as against a 39 per cent rally in the S&P BSE Sensex.
The Competition Commission of India (CCI) has approved a proposed deal involving Serum Institute Life Sciences, Covidshield Technologies and Biocon Biologics. Once the deal is complete, Serum Institute Life Sciences Pvt Ltd will have about 15 per cent stake in Biocon Biologics Ltd, according to the notice filed with the regulator. Covidshield Technologies Pvt Ltd (CTPL), a wholly-owned subsidiary of Serum Institute of Life Sciences, will be merged into Biocon Biologics. In a tweet on Wednesday, the watchdog said it has cleared the "merger by absorption of Covidshield Technologies into Biocon Biologics in consideration for acquisition of approximately 15 per cent equity shareholding of Biocon Biologics by Serum Institute Life Sciences." CTPL was incorporated to undertake the business of marketing, selling and distributing vaccines, drugs and other pharmaceutical products. Biocon Biologics Ltd is a subsidiary of Biocon Ltd. It offers treatment for chronic and acute diseases such as
Stocks to Watch: The US markets suffered the biggest one-day sell-off in almost two years -Investors worry about inflation and its impact on earnings and prospects for monetary policy tightening
Biocon Biologics is a subsidiary of Biocon Ltd
The BJP used the signing of MoU for setting up the largest semiconductor fabrication unit in Karnataka to hit out at Shaw